[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,31(11):124-126,129.[doi:10.3969/j.issn.1006-1959.2018.11.039]
　PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2018,31(11):124-126,129.[doi:10.3969/j.issn.1006-1959.2018.11.039]
点击复制

吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年11期
页码:
124-126,129
栏目:
药物与临床
出版日期:
2018-06-01

文章信息/Info

Title:
Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma
文章编号:
1006-1959（2018）11-0124-04
作者:
彭玉龙; 张 露; 陈荣辉; 曹永新; 邓惠君
中山大学附属东华医院肿瘤内科，广东 东莞 523110
Author(s):
PENG Yu-long; ZHANG Lu; CHEN Rong-hui; CAO Yong-xin; DENG Hui-jun
Department of Oncology,Donghua Hospital Affiliated to Sun Yat-sen University,Dongguan 523110,Guangdong,China
关键词:
肺腺癌; 吉西他滨; 培美曲塞; 卡铂; 血CEA
Keywords:
Key words：Lung adenocarcinoma; Gemcitabine; Pemetrexed; Carboplatin; Blood CEA
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.11.039
文献标志码:
A
摘要:
目的 探讨吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的疗效及其对血癌胚抗原的影响。方法 选取2013年6月~2016年9月中山大学附属东华医院收治的晚期肺腺癌患者85例作为研究对象，随机分为对照组42例和观察组43例。在常规治疗基础上，对照组采用吉西他滨联合卡铂的化疗方案，观察组则采用培美曲塞联合卡铂的化疗方案。观察比较两组患者的治疗有效率，治疗前后的血清CEA以及不良反应的发生情况。结果 治疗后观察组治疗有效率为37.21%，对照组治疗有效率为30.95%，两组比较差异无统计学意义(P＞0．05)。治疗前两组 CEA水平对比，差异无统计学意义(P＞0．05)，治疗后观察组血CEA为（32.35±4.73）ng/ml，低于对照组（46.63±5.12）ng/ml，组间差异有统计学意义（P＜0.05）。此外，观察组中性粒细胞减少、贫血以及血小板减少发生率低于对照组，差异有统计学意义(P＜0．05)。结论 培美曲塞联合卡铂与吉西他滨联合卡铂治疗晚期肺腺癌患者的临床疗效相当，但培美曲塞组可明显降低血CEA水平，且不良反应发生率低，安全性好。
Abstract:
Abstract：Objective To investigate the efficacy of gemcitabine combined with pemetrexed combined with carboplatin in the treatment of advanced lung adenocarcinoma and its effect on hepatocarcinoembryonic antigen.Methods A total of 85 patients with advanced lung adenocarcinoma admitted to Donghua Hospital of Sun Yat-sen University from June 2013 to September 2016 were selected as study objects.They were randomly divided into a control group of 42 cases and an observation group of 43 cases.On the basis of conventional treatment,the control group received a chemotherapy regimen of gemcitabine plus carboplatin,while the observation group used a chemotherapy regimen of pemetrexed combined with carboplatin.The efficacy of treatment,the serum CEA before and after treatment,and the occurrence of adverse reactions were observed and compared between the two groups.Results After treatment,the effective rate was 37.21% in the observation group and 30.95% in the control group.There was no significant difference between the two groups(P>0.05).There was no significant difference in CEA levels between the two groups before treatment(P>0.05). After treatment,CEA in the observation group was(32.35±4.73)ng/ml,which was lower than that of the control group(46.63±5.12)ng/ml. There was a statistically significant difference between groups(P<0.05).In addition,the incidence of neutropenia,anemia,and thrombocytopenia was lower in the observation group than in the control group,with a significant difference(P<0.05).Conclusion The clinical efficacy of pemetrexed combined with carboplatin and gemcitabine combined with carboplatin in the treatment of advanced lung adenocarcinoma is similar,but pemetrexed can significantly reduce blood CEA levels,and the incidence of adverse reactions is low, and safety is good.

参考文献/References:

[1]Ryerson AB,Eheman CR,Ahekruse SF,et al．Annual reportto the nation on the status of cancer,1975-2012,featuringthe increasing incidence of liver cancer[J]．Cancer,2016,122(9):1312-1337． [2]Dimitroulis J,Stathopoulos GP．Evolution of non-small celllung cancer chemotherapy(Review)[J]．Oncol Rep,2005,13(5):923-930． [3]Jiang AG,Chen HL,Lu HY．The relationship between glas-gow prognostic score and serum tumor markers in patientswith advanced non-small cell lung cancer[J]．Bmc Cancer,2015,15(1):1-6． [4]Arriagada R,Aupefin A,Burdett S,et al．Adjuvant chemo-therapy,with or without postoperative radiotherapy,in operablenon-small．cell lung cancer:two meta-analyses of individualpatient data[J]．Lancet,2010,375(9722):1267-1277． [5]田伟，豆亚伟，戴云，等．不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性研究[J]．河北医学，2016，22(8)：1305-1307． [6]王智辉，刘裕杰，吴庭安，等 培美曲塞联合卡铂与吉西他滨联合卡铂治疗非小细胞肺癌的疗效对比研究[J].广西医学，2013,35(08):1000-1002. [7]Bover I,Begbie S,Tzekova V,et al．Maintenance peme-trexed plus best supportive care versus placebo plus bestsupportive care for non-small-cell lung cancer:a randomised double-blind,phase 3 study[J]．Lancet,2009,374 (9699):1432-1440． [8]Lee JH,Yu CK,Shih JY,et al．Pemetrexed for heavily pretreatedpatients with advanced non-small cell lung cancer[J]．J Formos Med Assoc,2010,109(5):338-344． [9]Cedr6s S,Nufiez I,Longo M,et al．Serum tumor markersCEA,CYFRA21-1,and CA-125 are associated with worseprognosis in advanced non-small-cell lung cancer(NSCLC)[J]．Clin Lung Cancer,2011,12(3):172-179． [10]Jiang AG,Chen HL,Lu HY．The relationship between glasgowprognostic score and selum tumor markers in patientswith advanced non-small cell lung cancer[J]．Bmc Cancer,2015,15(1):1-6．

相似文献/References:

[1]刘治利,葛明建.肺部磨玻璃结节的CT特征与治疗策略进展[J].医学信息,2018,31(11):49.[doi:10.3969/j.issn.1006-1959.2018.11.016]
　LIU Zhi-li,GE Ming-jian.Advances in CT Features and Treatment Strategies of Pulmonary Ground-glass Nodule[J].Journal of Medical Information,2018,31(11):49.[doi:10.3969/j.issn.1006-1959.2018.11.016]
[2]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
　LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Journal of Medical Information,2019,32(11):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
[3]葛丽艳,王 琦,朱 宏,等.基于数据挖掘分析GPR35表达对肺腺癌预后的影响[J].医学信息,2018,31(23):86.[doi:10.3969/j.issn.1006-1959.2018.23.024]
　GE Li-yan,WANG Qi,ZHU Hong,et al.The Effect of GPR35 Expression on Prognosis of Lung Adenocarcinoma was Analyzed Based on Data Mining[J].Journal of Medical Information,2018,31(11):86.[doi:10.3969/j.issn.1006-1959.2018.23.024]
[4]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
　LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Journal of Medical Information,2019,32(11):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[5]黄琪峰,郑琳琳,张 菁.生物信息学分析筛选肺腺癌靶基因及评估预后的价值[J].医学信息,2019,32(22):62.[doi:10.3969/j.issn.1006-1959.2019.22.020]
　HUANG Qi-feng,ZHENG Lin-lin,ZHANG Jing.Bioinformatics Analysis of Screening Lung Adenocarcinoma Target Genes and Evaluating Prognostic Value[J].Journal of Medical Information,2019,32(11):62.[doi:10.3969/j.issn.1006-1959.2019.22.020]
[6]唐怀慧,王忠帅,邵茜茜,等.基于TCGA数据库肺腺癌RNAs构建ceRNA网络的综合分析[J].医学信息,2020,33(07):90.[doi:10.3969/j.issn.1006-1959.2020.07.025]
　TANG Huai-hui,WANG Zhong-shuai,SHAO Qian-qian,et al.Comprehensive Analysis of Constructing ceRNA Network Based on TCGA Database of Lung Adenocarcinoma RNAs[J].Journal of Medical Information,2020,33(11):90.[doi:10.3969/j.issn.1006-1959.2020.07.025]
[7]莫俊贤,冼 磊.miRNA-21及PTEN在肺腺癌组织中的表达及意义[J].医学信息,2020,33(09):77.[doi:10.3969/j.issn.1006-1959.2020.09.022]
　MO Jun-xian,XIAN Lei.Expression and Significance of miRNA-21 and PTEN in Lung Adenocarcinoma[J].Journal of Medical Information,2020,33(11):77.[doi:10.3969/j.issn.1006-1959.2020.09.022]
[8]李 敖,王玉然,王文浩.基于公共数据库分析自噬相关基因在肺腺癌患者中的预后意义[J].医学信息,2022,35(22):17.[doi:10.3969/j.issn.1006-1959.2022.22.003]
　LI Ao,WANG Yu-ran,WANG Wen-hao.Prognostic Significance of Autophagy-related Genes in Patients with Lung Adenocarcinoma Based on Public Database Analysis[J].Journal of Medical Information,2022,35(11):17.[doi:10.3969/j.issn.1006-1959.2022.22.003]
[9]孔德伟,吴 铭,张 岩.肺腺癌骨转移肿瘤标记物的研究进展[J].医学信息,2022,35(23):171.[doi:10.3969/j.issn.1006-1959.2022.23.038]
　KONG De-wei,WU Ming,ZHANG Yan.Research Progress on Tumor Markers of Bone Metastasis in Lung Adenocarcinoma[J].Journal of Medical Information,2022,35(11):171.[doi:10.3969/j.issn.1006-1959.2022.23.038]
[10]思 璐,秦秋雯,沈 印,等.基于生物信息学分析筛选肺腺癌免疫预后相关lncRNA[J].医学信息,2023,36(01):1.[doi:10.3969/j.issn.1006-1959.2023.01.001]
　SI Lu,QIN Qiu-wen,SHEN Yin,et al.Screening of lncRNA Related to Immune Prognosis of Lung Adenocarcinoma Based on Bioinformatics Analysis[J].Journal of Medical Information,2023,36(11):1.[doi:10.3969/j.issn.1006-1959.2023.01.001]

更新日期/Last Update: 2018-06-01